The HNRNPLL Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the SK-HEP-1 human hepatic adenocarcinoma cell line, engineered to disrupt the endogenous HNRNPLL locus. This gene-edited pool, generated using CRISPR/Cas9-mediated gene disruption, provides a heterogeneous loss-of-function model to study the functional consequences of HNRNPLL ablation. The polyclonal format preserves cellular diversity while eliminating wild-type expression of the target gene across the population, making it suitable for assays that require pooled knockout cells. Unlike monoclonal isolates, this population maintains the natural genetic background variability of the parental line, which can be advantageous for studying gene function in a heterogeneous cancer cell context.
The SK-HEP-1 host cell line was originally established from the ascites of a patient with liver adenocarcinoma and exhibits an adherent epithelial morphology. Widely employed as a model for hepatocellular carcinoma research, SK-HEP-1 cells display robust metabolic and proliferative activity, making them valuable for studying liver cancer biology and drug metabolism. This cell line retains key signaling pathways relevant to hepatic tumorigenesis and serves as a platform for investigating the molecular mechanisms underlying HCC progression, metastasis, and therapeutic resistance. The integration of HNRNPLL knockout into this well-characterized hepatic carcinoma background creates a powerful system to explore the intersection of alternative splicing regulation and liver cancer.
HNRNPLL encodes a heterogeneous nuclear ribonucleoprotein that functions as a sequence-specific RNA-binding protein and master regulator of alternative splicing. In T lymphocytes, HNRNPLL is activated downstream of the TCR/CD3 complex and the LCK and ZAP70 kinases, where it critically governs the splicing of CD45 pre-mRNA to generate the RO and RB isoforms that modulate TCR signaling sensitivity. HNRNPLL interacts with core splicing factors such as U2AF2 and SF1 and is positioned within a signaling axis that includes CD45, LCK, ZAP70, LAT, ERK, and NFAT. Its activity is further influenced by IL-2 signaling, integrating extracellular cues with post-transcriptional gene regulation. By binding to specific RNA motifs, HNRNPLL promotes exon inclusion or skipping, thereby shaping the isoform landscape of target transcripts involved in immune cell activation, proliferation, and differentiation. Its dysregulation has been implicated in autoimmunity, immunodeficiency, and aberrant splicing in tumors.
Although HNRNPLL is best characterized in the immune system, its expression and functions in non-immune cells, including hepatic lineages, are increasingly recognized. In the SK-HEP-1 hepatic adenocarcinoma model, HNRNPLL knockout allows dissection of its role in alternative splicing events that may contribute to tumor cell phenotypes such as proliferation, survival, and metabolic adaptation. By eliminating HNRNPLL function in a liver cancer context, researchers can identify HNRNPLL-dependent splicing alterations and their downstream effects on oncogenic pathways. This model is particularly relevant for investigating how splicing dysregulation intersects with HCC biology and may reveal novel biomarkers or therapeutic targets. The polyclonal nature ensures that the knockout population retains the genetic heterogeneity typical of solid tumors, enhancing the translational relevance of the findings.
This polyclonal knockout product supports a wide range of experimental applications, including quantitative analysis of splicing isoform changes via RT-qPCR, global splicing profiling by RNA-seq, and protein isoform characterization by Western blotting. Co-immunoprecipitation assays can be employed to study HNRNPLL??s interactions with the splicing machinery, while functional assays such as proliferation and metabolic activity measurements enable assessment of phenotypic consequences of HNRNPLL loss. Moreover, the cells can be utilized in co-culture systems to explore interactions with immune cells or to study the impact of altered splicing on tumor cell behavior. For detailed protocols, validation data, or purchasing inquiries, please contact Ascent Research.
